Sterne Agee Raises Actavis plc Estimates, Price Target
Following a meeting with Actavis’ management, analysts at Sterne Agee increased the earnings estimates and price target on Actavis plc (NYSE: ACT).
Analyst Shibani Malhotra stated,”we raise the price target from $255 to $272 and remain buyers of Actavis on a fundamental basis.”
Analysts also raised third and fourth quarter 2014 earnings estimates to $3.03 per share and $3.41 per share.
Full year 2014 EPS estimates were raised to $13.25 from $13.02.
In addition, Actavis's Watson Labs Dorzolamide Hydrochloride, Timolol, Maleate ANDA was approved by the FDA.
Shares of Actavis are traded recently at $231.01, up 1.08 percent.
Latest Ratings for ACT
|Apr 2015||Leerink Swann||Maintains||Outperform|
|Mar 2015||Sterne Agee||Maintains||Buy|
© 2015 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.